Acetylsalicylic Acid Compared with Enoxaparin for the Prevention of Thrombosis and Mechanical Ventilation in COVID-19 Patients: A Retrospective Cohort Study.

BACKGROUND AND
OBJECTIVE: Low-dose acetylsalicylic acid (ASA, aspirin) is a well-known and frequently studied drug for primary and secondary prevention of disease due to its anti-inflammatory and coagulopathic effects. COVID-19 complications are attributed to the role of thrombo-inflammation. Studies regarding the use of low-dose ASA in COVID-19 are limited. For this reason, we propose that the use of low-dose ASA may have protective effects in COVID-19-related thromboembolism and lung injury. This study was conducted to assess the efficacy of low-dose ASA compared with enoxaparin, an anticoagulant, for the prevention of thrombosis and mechanical ventilation.
METHODS: We conducted a retrospective cohort study on COVID-19-confirmed hospitalized patients at the Mansoura University Quarantine Hospital, outpatients, and home-isolated patients from September to December 2020 in Mansoura governorate, Egypt. Binary logistic regression analysis was used to assess the effect of ASA compared with enoxaparin on thromboembolism, and mechanical ventilation needs.
RESULTS: This study included 225 COVID-19 patients. Use of ASA-only (81-162 mg orally daily) was significantly associated with reduced thromboembolism (OR 0.163, p = 0.020), but both low-dose ASA and enoxaparin, and enoxaparin-only (0.5 mg/kg subcutaneously (SC) daily as prophylactic dose or 1 mg/kg SC every 12 hours as therapeutic dose) were more protective (odds ratio [OR] 0.010, OR 0.071, respectively, p < 0.001). Neither ASA-only nor enoxaparin-only were associated with a reduction in mechanical ventilation needs. Concomitant use of low-dose ASA and enoxaparin was associated with reduced mechanical ventilation (OR 0.032, 95% CI 0.004-0.226, p = 0.001).
CONCLUSIONS: Low-dose ASA-only use may reduce the incidence of COVID-19-associated thromboembolism, but the reduction may be less than that of enoxaparin-only, and both ASA and enoxaparin. Concomitant use of ASA and enoxaparin demonstrates promising results with regard to the reduction of thrombotic events, and mechanical ventilation needs.

Key Points

Introduction

The COVID-19 pandemic has had a devastating impact globally. COVID-19 manifests with a wide spectrum of clinical presentations including asymptomatic (40–45%) [1] or symptomatic, with symptomatic cases further classified as mild (40%), moderate (40%), severe (15%), and critical (5%). Patients with severe or critical illness develop complications such as acute respiratory distress syndrome (ARDS), septic shock, thromboembolism, and/or multiple organ dysfunction [2]. The pathogenesis of these complications is poorly characterized but thought to be due to a combination of severe inflammation, platelets activation, endotheliopathy, and coagulopathy [3-6].

Thromboembolic events are frequently observed in COVID-19 patients (16–31%) and are likely most common in the moderate-to-severe cases that are often encountered in the hospitalized setting [7-9]. One study noted a high incidence of venous thromboembolic (VTE) complications in hospitalized COVID-19 patients (26%), with 12% of patients having pulmonary embolism (PE) with or without deep venous thrombosis (DVT) and 14% with DVT alone [10]. Little is known about the incidence of thrombosis in the outpatient setting especially for those with mild disease. Reports have described precipitous embolic events in mild disease managed in the outpatient setting necessitating emergent hospitalization [11]. COVID-19 patients may be predisposed to both arterial and or venous thrombosis [12]. In a recent study, the incidence of arterial thrombosis was observed to be about twice that of VTE in hospitalized COVID-19 patients (11.1% vs 6.2%) [9].

Low-dose acetylsalicylic acid (ASA, aspirin) may have a putative role in targeting the pathogenesis of COVID-19 complications through its anti-inflammatory, antiplatelet aggregation, anticoagulant effects, and pleiotropic effects on endothelial function [13, 14], as well as its antiviral activity against RNA viruses in the respiratory tract [15]. Low-dose ASA is recommended for secondary prevention of arterial thrombosis in COVID-19 [16, 17], further studies described a possible role in primary prevention of arterial thrombosis as well [11, 14, 18]. Use of ASA in COVID-19 patients prior to hospitalization may have an important role in prevention of ARDS and mortality [19]. Prior to COVID era, a meta-analysis concluded that antiplatelet therapies such as ASA were associated with a lower incidence of ARDS and reduced mortality in critically ill patients [20].

A recent retrospective cohort study found that ASA use in hospitalized COVID-19 patients was associated with decreased risk of mechanical ventilation, intensive care unit (ICU) admission, and in-hospital mortality [21]. A propensity-matched retrospective study revealed that in-hospital ASA compared to no antiplatelet therapy was associated with a significantly reduced cumulative incidence of in-hospital mortality among hospitalized adult patients with COVID-19 (hazard ratio 0.522 [0.336–0.812]) [22]. A recent meta-analysis concluded that low-dose ASA use during or prior to hospitalization was associated with a significant reduction in mortality among patients with COVID-19 [23]. Yuan et al found that prehospital ASA use was not associated with decreased mortality in hospitalized COVID-19 patients with coronary artery disease [24]. Another recent meta-analysis supported this finding [25].

Data regarding the protective effects of ASA therapy on arterial thrombosis, and risk of mechanical ventilation are limited. This study aims to assess the effectiveness of low-dose ASA compared with enoxaparin (ENX) for the prevention of thrombotic events, and mechanical ventilation need.

Methods

Study Design and Patients

We conducted a retrospective cohort observational study between September and December 2020. Ethical approval was obtained from the Institutional Review Board (IRB) at Mansoura University (code number: R.20.08.971).

Convenience sampling was used on 234 COVID-19 patients, who were aged at least 18 years, and had a confirmed SARS-CoV-2 infection by the qualitative real-time polymerase chain reaction (RT-PCR) of a nasal swab. Nine patients were excluded because they were pregnant, had a history of end-stage renal disease with coagulopathy, and had inadequate laboratory and/or radiological data. Consequently, 225 COVID-19 patients were included in this study.

Data, Definitions, and the Perceived Treatment

Demographics, comorbidities, laboratory, and radiological data of hospitalized patients were aretrieved from the medical records at Mansoura University's Quarantine Hospital, Mansoura governorate, Egypt. Similar data were retrieved, as complete as possible, from home-isolated patients and patients who preferred outpatient follow-up. Radiological data included chest computed tomography (CT) findings (e.g. ground glass opacity [GGO], crazy-paving pattern, pulmonary consolidation, fibrosis, sub-pleural lines, and the halo sign), which were defined according to the standard glossary for thoracic imaging reported by the Fleischner Society [26]. A semi-quantitative CT severity scoring proposed by Pan et al was calculated per each of the 5 lobes considering the extent of anatomic involvement, as follows: 0: no involvement; 1: <5% involvement; 2: 5–25% involvement; 3: 26–50% involvement; 4: 51–75% involvement; 5: > 75% involvement. Summation of each individual lobar score resulted in a global CT score (0–25) [27].

COVID-19 cases were classified according to WHO definition and are defined as follows: moderate COVID-19 defined as the presence of clinical signs of pneumonia (fever, cough, dyspnea, fast breathing) but no signs of severe pneumonia, including oxygen saturation by pulse oxymetry (SpO2) ≥ 90% on room air, severe COVID-19 defined by the presence of oxygen saturation < 90% on room air or respiratory rate > 30 breaths per minute in adults or presence of signs of severe respiratory distress, i.e., accessory muscle use, inability to complete full sentences; critical COVID-19 defined as the presence of ARDS, sepsis, septic shock or the need for vasopressor therapy or non-invasive or invasive mechanical ventilation [2].

Patients were categorized as control group (who do not receive ASA, others antiplatelet agents, ENX, or others anticoagulant), ASA alone, ENX alone, or both ASA and ENX (ASA-ENX). ASA group included COVID-19 patients who were released for home isolation or presented with a primary thromboembolic event and were not on an anticoagulant. Patients with concomitant antiplatelet therapies were excluded from ASA group.

Use of ASA was defined as administration of low-dose ASA (81–162 mg orally [PO] daily) for other underlying conditions within 7 days prior to—or within 24 h of COVID-19 diagnosis. This definition was based on the rapid onset (0–4 h) and the prolonged duration of action of ASA when chewed or swallowed. The irreversible platelet-inhibitory effects of ASA can last for the life span of human platelets (7–10 days) [28, 29].

Enoxaparin, an injectable low-molecule weight heparin (LMWH), was the only received anticoagulant in our sample. Enoxaparin intake was defined as receiving ENX for other underlying conditions prior to hospital admission, or after the diagnosis of COVID-19. According to the Egyptian protocol of COVID-19 management, prophylactic dose enoxaparin sodium (0.5 mg/kg subcutaneously [SC] daily) was administrated for hospitalized patients with moderate COVID-19 and having D-Dimer 500–1000 ng/mL. Therapeutic dose (1 mg/kg SC every 12 hours) was administrated for hospitalized patients with moderate COVID-19 and having D-Dimer more than 1000 ng mL or hospitalized patients with severe or critical COVID-19. Thus, enoxaparin was not prescribed to non-hospitalized patients [30].

In our study, patients with moderate COVID-19 received oral hydroxychloroquine (400 mg twice per day on first day then 200 mg twice per day for 6 days) plus oral ivermectin (36 mg on day [0-3-6]). while moderate COVID-19 patients with a high risk and arterial oxygen saturation (SaO2) < 92% received remdesivir (200 mg intravenously [IV] on Day 1 followed by 100 mg IV daily for 5 days). Remdesivir was also prescribed for patients with severe or critical COVID-19. Steroids (dexamethasone 6 mg IV or its oral equivalent) were prescribed for patients with moderate COVID-19 who had severe dyspnea, a respiratory rate more than 24 breaths/min or their CT showed rapid deterioration, while steroids (dexamethasone 6 mg IV or methylprednisolone 1 mg/kg/24 h) were administrated for those patients with severe or critical COVID-19 [30].

Outcomes

The primary outcome was the occurrence of thrombotic events, defined prior to implementing this study as DVT, pulmonary embolism, peripheral arterial occlusion, ischemic stroke, ST-elevation myocardial infarction, or bowel ischemia. In our study, thromboembolic events were arterial events. Cardiologists diagnosed COVID-19 cases with coronary artery disease using echocardiogram and cardiac enzymes, while neurologists diagnosed stroke in COVID-19 patients using CT brain scan.

Another study outcome showed the need for mechanical ventilation following a diagnosis of COVID-19. Indications of invasive mechanical ventilation in our study were: failed non-invasive ventilation, or not available or not practical, partial pressure of oxygen (PO2) < 60 mmHg despite oxygen supplementation, progressive hypercapnia, respiratory acidosis (PH < 7.30), progressive or refractory septic shock, disturbed consciousness level (Glascow coma score ≤ 8) or deterioration of consciousness level from baseline [30].

Statistical Analysis

All statistical analyses were performed using IBM SPSS Statistics for Windows, version 25 (IBM Corp., Armonk, NY, USA). Categorical variables were presented as number and percentage of patients and were compared between groups using the Chi-squared or Fisher’s exact tests. Continuous variables were presented as mean ± standard deviation (SD), and tested for normality with the Kolmogorov-Smirnov test. Nonparametric continuous variables were compared among groups using the Kruskal Wallis Test and the p values were adjusted for multiple comparisons using Bonferroni Correction. Binary logistic regression models were fitted to determine the adjusted associations between ASA use and outcomes (i.e. thrombotic events, and the need for mechanical ventilation) after controlling for confounders. Selection of confounders was guided by the significance level in bivariate associations, collinearity, the change in model’s R-square, and in published literature recommendations. Selected confounders included patient’s age, previous comorbidities such as diabetes, hypertension, established cardiovascular diseases (CVD), and COVID-19 severity. p values < 0.05 were considered statistically significant.

Results

This study included 225 patients with a confirmed diagnosis of COVID-19. Patients on ASA, ENX, or both were significantly older than patients not on these medications (p < 0.001), while there was no statistically significant difference between sexes. Diabetes mellitus, hypertension, and stroke were the most frequent comorbidities observed amongst patients receiving both ASA and ENX, while cardiac and coronary artery diseases were most frequent among patient receiving ASA alone. The majority of patients on either ENX alone or both ASA and ENX had severe COVID-19 (79.7% and 88.6%, respectively), while 64.5% of patients on ASA alone had moderate COVID-19 (p < 0.001) (Table 1).

Table 1

Demographic and clinical characteristics, and outcomes of the study groups (N = 225)

Variable	Control (n = 36)	ASA alone (n = 31)	ENX alone (n = 123)	ASA-ENX (n = 35)	p-value
Age (y), mean ± SD (range)	44 ± 16.5	56 ± 16.1**	58 ± 14.7**	61 ± 14.3**	< 0.001*
	(20–75)	(25–85)	(25–90)	(33–88)
Age category (y)
< 45	16 (44.4%)	9 (29.0%)	24 (19.5%)	6 (17.1%)	0.018*
45–65	17 (47.2%)	12 (38.7%)	58 (47.2%)	19 (54.3%)
> 65	3 (8.3%)	10 (32.3%)	41 (33.3%)	10 (28.6%)
Patient sex
Female	24 (66.7%)	15 (48.4%)	66 (53.7%)	18 (51.4%)	0.426
Male	12 (33.3%)	16 (51.6%)	57 (46.3%)	17 (48.6%)
Comorbidities
None	24 (66.7%)	9 (29.0%)	44 (35.8%)	6 (17.1%)	NA
Diabetes mellitus	4 (11.1%)	12 (38.7%)	53 (43.1%)	17 (48.6%)	0.003*
Hypertension	5 (13.9%)	15 (48.4%)	56 (45.5%)	22 (62.9%)	<0.001*
Asthma	2 (5.6%)	1 (3.2%)	6 (4.9%)	3 (8.6%)	0.766
Cardiac/coronary artery disease	0	8 (25.8%)	4 (3.3%)	8 (22.9%)	<0.001*
Stroke	2 (5.6%)	4 (12.9%)	4 (3.3%)	6 (17.1%)	0.014*
Gastrointestinal symptoms	2 (5.6%)	8 (25.8%)	26 (21.1%)	11 (32.4%)	0.041*
COVID-19 severity (on-diagnosis)
Moderate	29 (80.6%)	20 (64.5%)	25 (20.3%)	4 (11.4%)	< 0.001*
Severe/critical	7 (19.4%)	11 (35.5%)	98 (79.7%)	31 (88.6%)
SPO2% (on-admission), mean ± SD (range)	92.30± 9.1 (59–99)	91.9 ± 4.7 (80–98)	82.7 ± 12.1 (48–98)***	85.2 ± 8.6 (62–97)***	<0.001*
Ventilatory support (on-diagnosis)
Room-air	25 (69.4%)	13 (41.9%)	21 (17.1%)	4 (11.4%)	<0.001*
Oxygen therapy	10 (27.8%)	16 (51.6%)	80 (65.0%)	30 (85.7%)
Continuous positive airway pressure	1 (2.8%)	2 (6.5%)	11 (8.9%)	1 (2.9%)
Invasive mechanical ventilation	0	0	11 (8.9%)	0
Outcomes
Thromboembolic events	11 (30.6%)	8 (25.8%)	21 (17.1%)	2 (5.9%)	0.042*
Need for mechanical ventilation	6 (16.7%)	11 (35.5%)	49 (39.8%)	7 (20.0%)	0.021*

NA not applicable, ASA acetylsalicylic acid, ASA-ENX both acetylsalicylic acid and enoxaparin, ENX enoxaparin, SpO oxygen saturation

*Statistically significant p value (< 0.05); Kruskal Wallis Test for age and SPO2%; Chi-square or Fisher’s for other categorical variables

**Significantly different from the control group (p value adjusted for multiple comparisons with Bonferroni Correction)

***Significantly different from the ASA group (p value adjusted for multiple comparisons with Bonferroni Correction)

Thrombo-embolic events included cerebrovascular stroke and myocardial infarction. Cerebrovascular stroke represented the majority of events in the control, ASA alone, and ASA-ENX groups (63.6%, 87.5%, and 100%, respectively), while myocardial infarction constituted 66.7% of all thrombo-embolic events in ENX alone group.

Radiological findings showed that patients on either ENX alone or both ASA and ENX had higher severity scores than patients on ASA alone or controls (p = 0.015). No statistically significant differences existed among the study groups regarding diagnostic laboratory findings with the exception of platelets count, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) (Table 2).

Table 2

Radiological and laboratory findings on diagnosis among the study groups (N = 225)

Findings	Control (n = 36)	ASA alone (n = 31)	ENX alone (n = 123)	ASA-ENX (n = 35)	p value
Total Lung Severity Score (n = 76), mean ± SD (range)	10.9 ± 5.5	9.7 ± 4.0	14.7 ± 4.9 a	15.3 ± 4.3	0.015*
	(0–19)	(2–15)	(5–25)	(9–20)
CT Phenotype (N = 193)	(n = 18)	(n = 28)	(n = 113)	(n = 34)
Type L	10 (55.6%)	15 (53.6%)	42 (37.2%)	17 (50.0%)	0.2
Type H	8 (44.4%)	13 (46.4%)	71 (62.8%)	17 (50.0%)
Hemoglobin (g/dL)	12.2 ± 1.8	11.5 ± 1.6	11.8 ± 1.9	11.6 ± 1.9	0.365
White blood cells (× 1000)	9.1 ± 7.4	8.6 ± 4.0	9.0 ± 4.5	9.2 ± 4.2	0.409
Lymphocytes (%)	25.9 ± 14.3	23.5 ± 16.3	19.7 ± 11.3	17.3 ± 13.4	0.327
Platelets (× 1000)	235.7 ± 110.4	210.3 ± 63.4	198.2 ± 80.3**	194.1 ± 63.5	0.045*
d-Dimer (ng/mL)	2300 ± 2700	1300 ± 1400	1200 ± 2000	500 ± 700	0.556
Ferritin (ng/mL)	451.6 ± 696.9	151.0 ± 146.1	228.4 ± 186.4	147.5 ± 96.9	0.846
C-reactive protein (mg/L)	63.6 ± 72.9	71.6 ± 53.5	48.4 ± 41.7	43.5 ± 31.6	0.377
Erythrocyte sedimentation rate (mm/hour)	31.7 ± 23.9	36.3 ± 31.2	37.4 ± 18.7	41.7 ± 40.2	0.873
Albumin (g/dL)	3.7 ± 0.8	3.3 ± 0.5	3.4 ± 0.6	3.5 ± 0.5	0.304
Alanine aminotransferase (U/L)	24.6 ± 12.0	31.8 ± 17.3	46.8 ± 42.4**	33.8 ± 17.3	0.001*
Aspartate aminotransferase (U/L)	25.5 ± 14.9	38.9 ± 20.1**	53.5 ± 47.9**	32.9 ± 15.7	<0.001*
Bilirubin (mg/dL)	1.0 ± 1.1	0.7 ± 0.2	0.8 ± 0.6	0.8 ± 0.2	0.752
Serum creatinine (mg/dL)	1.5 ± 1.9	1.5 ± 0.9	1.5 ± 2.7	1.2 ± 0.4	0.346

ASA acetylsalicylic acid, ASA-ENX both acetylsalicylic acid and enoxaparin, CT computed tomography, ENX enoxaparin

*Statistically significant p value (< 0.05); Kruskal Wallis Test and Fisher’s exact test

**Significantly different from the control group (p value adjusted for multiple comparisons with Bonferroni Correction)

aSignificantly different from the aspirin group (p value adjusted for multiple comparisons with Bonferroni Correction)

In multivariate analysis, thrombo-embolic events were significantly less likely to occur among patients on both ASA and ENX, ENX alone, or ASA alone when compared to control patients (OR 0.010, OR 0.071, and OR 0.163, respectively, p < 0.05) when adjusted for age, diabetes mellitus, hypertension, established CVD, and COVID-19 severity (Table 3). The need for mechanical ventilation, adjusted for patient’s age, diabetes mellitus, hypertension, established CVD, and COVID-19 severity, was less likely for patients on both ASA and ENX compared with control patients (OR 0.032, 95% CI 0.004–0.226, p = 0.001), Table 4.

Table 3

Logistic regression analysis for predicting thromboembolic events in the study groups (N = 225)

Variables	Adjusted modela		p value
	OR	95% CI
Constant	0.052		< 0.001*
Age (y)	1.034	1.000–1.069	0.047*
Severe/critical COVID-19 (vs moderate)	6.008	1.570–22.99	0.009*
Comorbidities
Diabetes mellitus (vs No)	0.867	0.367–2.051	0.746
Hypertension (vs No)	1.740	0.704–4.301	0.230
Established cardiovascular disease (vs No)	3.289	1.057–10.23	0.040*
Study groups (vs non-ASA and non-ENX)
Acetylsalicylic acid alone	0.163	0.035–0.752	0.020*
Enoxaparin alone	0.071	0.018–0.280	< 0.001*
Both acetylsalicylic acid and enoxaparin	0.010	0.001–0.078	< 0.001*

Variables entered on step 1: Age (y), COVID-19 Severity (severe/critical vs moderate), diabetes mellitus (Y/N), hypertension (Y/N), established cardiovascular disease (Y/N), and study groups (vs non-acetylsalicylic acid and non-anticoagulant)

ASA acetylsalicylic acid, CI confidence interval, ENX enoxaparin, OR odds ratio

*Statistically significant p value (< 0.05)

aBinary Logistic Regression Model: Hosmer and Lemeshow χ2 (df) = 5.926 (8), p = 0.655; Negelkerke R Square = 0.310; Overall correct classification = 83.9%

Table 4

Logistic regression analysis for predicting the need for mechanical ventilation in the study groups (N = 225)

Variables	Adjusted modela		p value
	OR	95% CI
Constant	0.002		< 0.001*
Age (years)	1.053	1.019–1.088	0.002*
Severe/critical COVID-19 (vs moderate)	69.00	10.43–456.7	< 0.001*
Comorbidities
Diabetes mellitus (vs No)	0.718	0.326–1.580	0.410
Hypertension (vs No)	2.414	1.066–5.466	0.035*
Established cardiovascular disease (vs No)	3.179	0.903–11.19	0.072
Study groups (vs non-ASA and non-ENX)
Acetylsalicylic acid alone	1.095	0.130–8.791	0.932
Enoxaparin alone	0.276	0.051–1.391	0.125
Both acetylsalicylic acid and enoxaparin	0.032	0.004–0.226	0.001*

Variables entered on step 1: Age (y), COVID-19 Severity (severe/critical vs moderate), diabetes mellitus (Y/N), hypertension (Y/N), established cardiovascular disease (Y/N), and study groups (vs non-acetylsalicylic acid and non-anticoagulant)

ASA acetylsalicylic acid, CI confidence interval, ENX enoxaparin, OR odds ratio

*Statistically significant p value (< 0.05)

aBinary Logistic Regression Model: Hosmer and Lemeshow χ2 (df) = 6.969 (8), p = 0.540; Negelkerke R Square = 0.541; Overall correct classification = 79.1%

Discussion

This retrospective cohort study found that the use of low-dose ASA alone, ENX alone, and both low-dose ASA and ENX was associated with a lower risk of thrombotic events. COVID-19 severity, the presence of established CVD, and increased age were the positive predictors of the development of these events. Concomitant use of ASA and ENX was associated with reduced mechanical ventilation need. The positive predictors of mechanical ventilation needs were COVID-19 severity, the presence of hypertension, and increased age.

In our study, vascular thrombotic events were significantly more frequent among control patients and patients on ASA alone compared with patients on ENX alone or both ASA and ENX. This finding in these non-hospitalized patients with moderate-to-severe COVID-19 is troubling as the risk for thrombosis is not limited exclusively to hospital settings.

Control patients had insignificant elevations of d-Dimer levels, C-reactive protein (CRP), and ferritin, which may reflect hypercoagulopathy and hyperinflammatory state. The pathogenesis of thrombi formation in these patients involves an evolution of Virchow’s triad: stasis from microthrombi, hyperviscosity, and immobility related to malaise; abnormal coagulability likely due to immune-mediated factors; and virus-associated endothelial damage. Individuals in the ASA alone group had comorbidities such as established cardiovascular diseases, diabetes mellitus and hypertension, which may outweigh the protective effect of ASA for CVD, promote disease escalation and abnormal coagulation and leave many patients vulnerable to escalation of illness severity.

All thrombotic events in our study were arterial thrombosis. Use of ENX or low-dose ASA in combination with ENX, may have contributed to the absence of venous thrombosis in our current study. The incidence rates of arterial thrombosis among control patients (30.6%), and patients on ASA alone (25.8%) or ENX alone (17.1%) were higher than the incidence rates described in previous studies [9, 31]. This finding may be related to our small sample size within each group. Prior studies found varied incidence rates of arterial thrombosis. A systematic review found that arterial thrombosis occurred in 4.4% of critically ill COVID-19 patients [31], while another meta-analysis described a higher incidence of thromboembolic events in hospitalized COVID-19 patients (7.2–40.8%) with a predominance of venous thromboembolic events [32]. Bilaloglu et al found that 11.1% of 3334 hospitalized COVID-19 patients developed arterial thrombosis [9].

Our study supports the use of low-dose ASA, ENX, and ASA plus ENX to reduce the risk of arterial thrombosis in COVID-19 patients; however, randomized control trials are needed to assess the causality effects of these therapies. These findings reflected the protective effect of low-dose ASA and ENX therapy on thrombosis in COVID-19 patients likely due to a combination of antithrombotic, anti-inflammatory, and antiviral effects in COVID-19 patients [33-35]. Administration of an anticoagulant is still recommended for hospitalized patients with COVID-19 unless there are other indications in non-hospitalized patients with COVID-19 [17].

Despite the effectiveness of ASA on thrombosis prevention in this study, ASA plus ENX therapy was more effective than ASA alone. This is possibly due to a synergistic or additive effect between these therapies. However, in our study we could not differentiate between the effect of low-dose ASA use for primary and secondary cardiovascular disease during pre-hospitalization or prior to home-isolation because of the small number of patients on low-dose ASA therapy for secondary prevention (26 patients). Chow et al [21] and Sahai et al [36] did not find an association between low-dose ASA use and prevention of thrombotic events; this finding is related to the lower percentage of reported thrombosis events in their sample.

We encourage the community to consider primary prophylaxis of thrombotic complications in individuals who may already be at an increased risk for thrombosis and test positive for COVID-19 in the outpatient setting. Our focus as a community, at times, seems to be on the treatment of those most critically ill, often neglecting those who fall in limbo between recovery and hospitalization. For this, we recommend the community consider the use of ASA for prevention of arterial and venous thrombotic events. With proper risk-stratification, the use of outpatient thromboprophylaxis may provide patients with a low-risk opportunity to defend against advanced disease while targeted therapy and vaccine production has time to be properly developed to be effective therapy.

According to our results, low-dose ASA was not effective in reducing the need for mechanical ventilation. In contrast, Chow et al found that low-dose ASA use was associated with reduced mechanical ventilation need [21]. Patients taking ASA in their study had less oxygen support on hospital admission and lower fibrinogen values. This could represent less severe illness and inflammatory states, which could conceivably produce a more favorable outcome [37]. Nevertheless, our study demonstrated that low-dose ASA plus ENX was associated with decreased mechanical ventilation needs. This reflects the protective and desirable effect of both ASA and ENX. A finding that enoxaparin alone was not associated with decreased rate of mechanical ventilation is incongruent with a previous study regarding reduced mechanical ventilation with therapeutic anticoagulant, which may be related to the limited sample size of ENX-only group in our study [38].

Enoxaparin was used in this study was due to provider preference and COVID-19 treatment protocols at the participating institution. Results from this study, while specific to enoxaparin, likely extend to other LMWHs (i.e. dalteparin), unfractionated heparin (UFH) and newer direct oral anticoagulants (DOACs) (i.e. betrixaban, rivaroxaban and apixaban) based on the proposed protective mechanism of thromboprophylaxis and the absence of known other unique therapeutic characteristics in COVID-19. Enoxaparin, dalteparin and UFH have shown comparable efficacy in the prevention of DVT in traumatic injuries [39]; however, while dalteparin was found to be non-superior to UFH in the prevention of DVT in critically ill patients, there was a noted reduction in the event of pulmonary embolus in the PROTECT trial [40].

Comparatively, between ENX and dalteparin, studies have not shown a difference in the prevention of DVT and PE for trauma patients [41]. Lastly, LMWH and DOACs have been thoroughly studied in acutely ill medical patients. The APEX trial reported no statistical difference in the efficacy of betrixaban versus ENX for the prevention of VTE [42], the Magellan trial reported a reduction in VTE in the rivaroxaban group when compared to ENX [43], and the ADOPT trial showed that apixaban was non-superior to ENX in the prevention VTE [44]. More studies are required to evaluate the efficacy of different anticoagulant agents in the prevention of VTE related to COVID-19.

To our knowledge, this is the first Egyptian study to assess the efficacy of low-dose ASA compared with ENX in the prevention of COVID-19-associated thrombosis, and mechanical ventilation.

This study has some limitations. Its observational design lacking randomization cannot establish causality. This study also suffered from a limited sample size, and single institutional analysis, so its result cannot be generalized. With the small number of participants on low-dose ASA, the effect of ASA use on primary and secondary atherosclerotic cardiovascular disease (ASCVD) could not be determined separately. Other confounders such as smoking, body mass index, and use of drugs for ASCVD prevention, especially statin, and other antiplatelet agents were not included in hospitalized patients. Lastly, the risk of bleeding associated with the use of ASA, ENX and concomitant ASA and ENX therapy was not assessed.

Conclusion

Use of low-dose ASA alone is significantly associated with a lower risk of COVID-19-related thromboembolism, but ENX alone, and both low-dose ASA and ENX were more effective than ASA in the reduction of thromboembolism. Concomitant ASA and ENX therapy are associated with a reduction in the need for mechanical ventilation. Further randomized control trials are needed to establish potential causal relationships.

Among COVID-19 patients, thromboembolic events were less likely to occur among patients on low-dose acetylsalicylic acid alone, but both acetylsalicylic acid and enoxaparin, and enoxaparin alone were more effective in reducing these events.

Use of acetylsalicylic acid alone and enoxaparin alone was not associated with a reduction in mechanical ventilation needs.

Concomitant use of low-dose aspirin and enoxaparin was associated with reduced mechanical ventilation.